Objective To systematically assess credibility and certainty of associations between
cannabis, cannabinoids, and cannabis based medicines and human health, from …

The management of orofacial pain to alleviate the quality of life of affected patients is
becoming increasingly challenging for scientific research and healthcare professionals …

Cannabidiol is a class of non-psychoactive plant cannabinoids derived from cannabis
plants. Currently, Epidiolex (Cannabidiol) has been approved by the FDA for the treatment of …

Chronic neuropathic pain is a debilitating pain syndrome caused by damage to the nervous
system that is poorly served by current medications. Given these problems, clinical studies …

Neuropathic pain is a condition that impacts a substantial portion of the population and is
expected to affect a larger percentage in the future. This type of pain is poorly managed by …

Abstract Purpose of Review Almost half of people diagnosed with diabetes mellitus will
develop painful diabetic neuropathy (PDN), a condition greatly impacting quality of life with …

Cannabinoids are proposed for alleviating neuropathic pain, but their use is limited by
cannabimimetic side effects. The inhibition of the fatty acid amide hydrolase (FAAH), the …

Abstract Purpose of Review Neuropathic pain (NP) remains a challenge to treat, with 50% of
patients experiencing limited efficacy from current treatments. Medicinal cannabis, which …

Introduction Cannabidiol (CBD) is a potential therapeutic for pain management. Yet, there
exists a dearth of studies of its tolerability and efficacy, especially in special populations …

Abstract Introduction The IASP ICD-11 chronic primary pain (CPP) definition includes 19
different painful conditions. In recent years, interest in the potential role of cannabinoids in …